Directorio

We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).

We are doing this study to compare the outcomes for women who use selumetinib alone and women who use selumetinib plus olaparib to treat endometrial or ovarian cancer. We want to know which option is better for women whose tumors harbor a mutation in a key survival pathway called KRAS.

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.

We are doing this study to find out the safety and effectiveness of Tumor Treating Fields (TTFields, 200 kHz) delivered by the Optune® device. We want to know if this experimental procedure can improve results for people who are being treated for GBM. We will compare how well this procedure works when it is given along with 2 different types of drug therapies.

We are doing this study to find out if an experimental drug called efgartigimod (the study drug) is a safe and effective option for people experiencing kidney rejection. We want to know if it can decrease antibody-mediated rejection following a transplant by removing the antibodies that target and damage the cells of the donated kidney.

This study has two parts. The first part tests different doses of a drug called EIS 12656 to learn about its safety and how the body handles it. The second part uses the best dose to study the drug in more people. You will be in the second part of the study. Doctors will do tests to see how your body and your cancer respond to the study drug. These tests may include physical exams, checking your vital signs, taking blood and urine samples, heart tests, scans, and tumor biopsies. You will also keep a diary to write down when you take the drug.

We are doing this study to test the safety and efficacy of elacestrant compared to standard of care therapy in people with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer with a high risk of coming back. We want to compare the effect of elacestrant to standard of care therapy. We want to know which option is most helpful for patient in doing their normal day to day activities, and to assess what the study drug does to the tumor markers that can be measured in your blood.